Tenax Therapeutics Inc (TENX) Given Consensus Recommendation of “Strong Buy” by Brokerages
Shares of Tenax Therapeutics Inc (NASDAQ:TENX) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a one year consensus target price of $6.63 for the company, according to Zacks. Zacks has also assigned Tenax Therapeutics an industry rank of 46 out of 255 based on the ratings given to related companies.
Separately, ValuEngine upgraded Tenax Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th.
An institutional investor recently bought a new position in Tenax Therapeutics stock. Geode Capital Management LLC acquired a new stake in Tenax Therapeutics Inc (NASDAQ:TENX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 27,658 shares of the specialty pharmaceutical company’s stock, valued at approximately $33,000. Geode Capital Management LLC owned 1.89% of Tenax Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 35.24% of the company’s stock.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Further Reading: Why is a lock-up period needed for an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.